Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors

Alzheimer Disease and Associated Disorders
B Winblad, Vesna Jelic

Abstract

During the past 20 years, research on Alzheimer disease (AD) and other dementias has increased our understanding of these disorders and has opened doors to new methods of treatment. Acetylcholinesterase inhibitors (AChEIs) have been successful in reducing symptoms in patients with mild-to-moderate AD and led to the US Food and Drug Administration's approval of four AChEIs for the treatment of AD. Although these agents are approved for only mild-to-moderate AD, and the available data for most of them are from trials of only 6 months' duration, long-term studies suggest that the benefits of AChEI treatment can endure for up to 4 years. A common pattern of response to treatment is initial improvement in cognition, followed by maintenance of cognitive gains above baseline for up to 1 year. Generally there is a decline in cognition to below baseline levels after approximately 1 year of treatment, but the level of cognition remains above that predicted for those not receiving pharmacologic treatment. Furthermore, long-term studies suggest that early diagnosis and treatment with AChEIs yield better long-term outcomes. Patients who received continuous pharmacologic treatment from the outset generally had better long-term outcomes than ...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Nov 11, 1992·JAMA : the Journal of the American Medical Association·M FarlowJ Dolan-Ureno
Nov 1, 1984·The American Journal of Psychiatry·W G RosenK L Davis
Mar 11, 1995·Lancet·K L Davis, P Powchik
Apr 6, 1994·JAMA : the Journal of the American Medical Association·M J KnappS I Gracon
Feb 7, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S L Rogers, L T Friedhoff
Mar 10, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·P T FrancisG K Wilcock
Apr 27, 1999·JAMA : the Journal of the American Medical Association·K L DavisV Haroutunian
May 20, 1999·The Annals of Pharmacotherapy·W J KrallN R Cutler
Sep 15, 1999·Alzheimer Disease and Associated Disorders·C H KawasP J Whitehouse
May 4, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S L RogersJ R Ieni
Mar 23, 2001·Acta Neurologica Scandinavica. Supplementum·M SamochockiA Maelicke
Aug 15, 2001·Neurology·B WinbladUNKNOWN Donepezil Nordic Study Group
Oct 19, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·K RockwoodD Wilkinson
Jul 16, 2003·Clinical Therapeutics·Timo ErkinjunttiUNKNOWN GAL-INT-6 Study Group
Aug 9, 2003·Nature Reviews. Drug Discovery·Ronald C Petersen

❮ Previous
Next ❯

Citations

Nov 9, 2007·European Archives of Psychiatry and Clinical Neuroscience·T LeyheC Laske
Nov 25, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·V JelicB Winblad
Sep 4, 2012·Neuropsychiatric Disease and Treatment·Piera SozioAntonio Di Stefano
Jan 13, 2006·International Review of Psychiatry·Paul B Rosenberg
Jun 1, 2006·Expert Review of Neurotherapeutics·Felix Mor, Alon Monsonego
Sep 16, 2005·Expert Review of Neurotherapeutics·Abhilash K Desai, George T Grossberg
Dec 24, 2005·Expert Opinion on Investigational Drugs·Ana Martinez, Ana Castro
Dec 2, 2008·Expert Opinion on Drug Delivery·Bengt Winblad, João Carlos Machado
Mar 23, 2011·Drug Development and Industrial Pharmacy·Kyung Hee Kim, Hye Sun Gwak
Mar 10, 2007·Experimental Neurology·Frank Lezoualc'h
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Kelly M CosmanAnton P Porsteinsson
Jul 8, 2009·The International Journal of Neuropsychopharmacology·Thomas LeyheChristoph Laske
May 14, 2014·Journal of Gerontological Social Work·Zina KallyMonica Villarruel
Oct 31, 2006·Biological Psychiatry·George Bartzokis
Sep 29, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Bharath Kumar VelmuruganChing-Feng Weng
May 26, 2010·International Journal of Clinical Practice·D W WrightM Laplaca
Oct 23, 2014·Archives of Pharmacal Research·So-Hyeon AhnByung-Joo Park
Nov 9, 2018·Frontiers in Aging Neuroscience·Muhammad OvaisZabta Khan Shinwari
Dec 23, 2020·ACS Chemical Neuroscience·Jared A Miles, Benjamin P Ross
Jul 25, 2017·ACS Chemical Neuroscience·Shahrina AlamCraig W Lindsley
Sep 13, 2011·Neurología : publicación oficial de la Sociedad Española de Neurología·J L MolinuevoUNKNOWN Grupo de Trabajo del Estudio TRACE

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.